Stay updated with breaking news from Alimera Sciences. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
StockNews.com began coverage on shares of Alimera Sciences (NASDAQ:ALIM – Get Rating) in a report published on Thursday morning. The firm issued a hold rating on the biopharmaceutical company’s stock. ALIM has been the topic of several other research reports. Zacks Investment Research lowered Alimera Sciences from a hold rating to a strong sell rating […]
/PRNewswire/ -- The Anterior Uveitis Treatment Market is poised to grow by USD 145.89 million from 2021 to 2026, progressing at a CAGR of 5.09% during the...
/PRNewswire/ -- The Anterior Uveitis Treatment Market is poised to grow by USD 145.89 million from 2021 to 2026, progressing at a CAGR of 5.09% during the...
The Global Retinal Vein Occlusion Market is expected to gain market growth at a potential rate of 10% in the forecast period of 2022 to 2029, helping market reach a capitalization of $22275.9 Million by the end of the forecasted period.Due to high demand and the value of market research for the success of different...
ALPHARETTA, Ga. (AP) _ Alimera Sciences Inc. (ALIM) on Thursday reported a loss of $4.1 million in its fourth quarter. The Alpharetta, Georgia-based company said it had a loss of 59 cents per share.